TSG101

Across TCGA pan-cancer cohorts, TSG101 RNA differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of TSG101’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where TSG101 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types TSG101 is over-expressed in tumor, although a few such as KICH and UCEC show the opposite, repressed pattern.

LIHC, BRCA, and CHOL are the cancer types where TSG101 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in TSG101 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	Female	III,IV	+1.046	<.001	9	view →
BRCA	All	III,IV	+0.594	<.001	6	view →
CHOL	Female	All	+1.786	<.001	5	view →
COAD	All	II,III,IV	+0.203	.012	5	view →
KICH	All	All	−0.497	<.001	4	view →
UCEC	All	All	−0.430	.018	2	view →
THCA	All	All	−0.122	.049	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

TSG101–LIHC

Open the LIHC breakdown →